Addition of Durvalumab, Bevacizumab to TACE Beneficial in Liver Cancer
By Elana Gotkine HealthDay Reporter
MONDAY, Jan. 29, 2024 -- For patients with embolization-eligible unresectable hepatocellular carcinoma (uHCC), the addition of durvalumab (D) and bevacizumab (B) to transarterial chemoembolization (TACE) improves progression-free survival (PFS), according to a study presented at the American Society of Clinical Oncology annual Gastrointestinal Cancers Symposium, held from Jan. 18 to 20 in San Francisco.
Riccardo Lencioni, M.D., from the University of Pisa School of Medicine in Italy, and colleagues randomly assigned patients with embolization-eligible uHCC to D + B + TACE, D + TACE, or TACE in a 1:1:1 ratio (204, 207, and 205 patients, respectively). The primary end point was PFS for D + B + TACE versus TACE.
The researchers found that PFS was significantly improved for D + B + TACE versus TACE (median, 15.0 versus 8.2 months; hazard ratio, 0.77). Across most prespecified subgroups, the results were consistent. The secondary end point of PFS for D + TACE versus TACE did not reach statistical significance. The objective response rate was 43.6, 41.0, and 29.6 percent, respectively, and median time to progression was 22.0, 11.5, and 10.0 months, respectively, for D + B + TACE, D + TACE, and TACE. Maximum grade 3/4 treatment-related adverse events occurred in 32.5, 15.1, and 13.5 percent, respectively; 0, 1.3, and 2.0 percent, respectively, died due to treatment-related adverse events.
"These results of the EMERALD-1 trial have the potential to establish a new standard of care for the treatment of unresectable hepatocellular carcinoma," Cathy Eng, M.D., ASCO expert in gastrointestinal cancers, said in a statement.
Several authors disclosed ties to pharmaceutical companies, including AstraZeneca, which manufactures durvalumab and funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted January 2024
Read this next
Direct-Acting Antivirals Still Underused in Hep C-Related Liver Cancer
TUESDAY, Nov. 21, 2023 -- Direct-acting antiviral agents (DAAs) remain underutilized in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC), according to...
Increasing Generational Status Linked to Elevated Risk for Liver Cancer
MONDAY, Nov. 20, 2023 -- For Mexican Americans, increasing generational status is associated with an increased risk for hepatocellular carcinoma (HCC), according to a study...
Hepatitis C Virus Still Leading Cause of Hepatocellular Cancer in Men
THURSDAY, Sept. 7, 2023 -- The leading cause of hepatocellular carcinoma (HCC) is still hepatitis C virus (HCV) among men, but the rates of HCV-HCC have decreased since 2015...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.